A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs FX 322 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions
- Sponsors Frequency Therapeutics
- 07 Jan 2019 According to a Frequency Therapeutics media release, top-line results are expected in the first half of 2019.
- 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2018 Status changed from planning to recruiting.